Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

PURPOSE: In MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2− metastatic breast cancer (MBC). To help interpret these results and put in clinical context, we compared over...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Dieras, Veronique, Cortes, Javier, Patt, Debra, Wildiers, Hans, O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Carter, Gebra Cuyun, Sheffield, Kristin M., Li, Li, Andre, Valerie A. M., Li, Xiaohong I., Frenzel, Martin, Huang, Yu-Jing, Dickler, Maura N., Tolaney, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568708/
https://www.ncbi.nlm.nih.gov/pubmed/32789591
http://dx.doi.org/10.1007/s10549-020-05838-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568708/
https://www.ncbi.nlm.nih.gov/pubmed/32789591
http://dx.doi.org/10.1007/s10549-020-05838-5

Ejemplares similares